All stock lists
Gyre Therapeutics, Inc. (NASDAQ:GYRE)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
4.28-0.37 (-7.97%)
Market cap
$454M
Insider Score
Health Score
Analyst consensus
Listed since
Apr 12, 2006
Website
Insider Score
––Not scored
GYRE Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
GYRE analyst forecast
No analyst ratings in the last 12 months
No independent sell-side analyst publishes on GYRE that our data provider carries. That is normal for smaller listings, and it is not a judgement on the company. Here is what we track instead:
- Insider activity and the Insider Score — what the people who run the company are doing with their own money.
- Promoter Scores — any disclosed paid stock promotion on this ticker.
Best analysts covering GYRE
No firm covering GYRE has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
GYRE earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | 0.06 | -0.02 | $35.4M | $37.2M |
| 2026-05-07 | -0.06 | -0.05 | $31.6M | $22.5M |
| 2026-08-07 | -0.06 | -0.12 | $26.5M | $29.1M |
| 2026-11-05 | -0.15 | 0.04 | $28.4M | $32.9M |
| 2027-03-11Upcoming | -0.16 | — | $29.5M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.